Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study

#1812

Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.

Aim(s): u5-HIAA is a commonly used serotonin marker in CS. Here, we investigated the potentially convenient alternative p5-HIAA.

Materials and methods: During DBT, 24h u5-HIAA and p5-HIAA levels were measured at baseline and every 6 weeks. Correlations were analysed between u5-HIAA and p5-HIAA at baseline, and 6 and 12 weeks.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,

Keywords: carcinoid syndrome, 5-HIAA, telotristat,